How to Get Vyvanse in Louisiana: Telehealth, Prescribers, and Pharmacy Access

The useful question for a Louisiana patient is rarely "is Vyvanse available here", it is federally scheduled and legal to prescribe in every state, but which specific steps (prescriber license type, telehealth video requirement, monthly re-prescribing, and payer documentation) actually determine whether a given patient gets it filled on time.

Louisiana permits telehealth prescribing of Vyvanse, but only with live video

Physicians, nurse practitioners, and physician assistants licensed in Louisiana can prescribe Schedule II controlled substances, including Vyvanse, if they hold a Louisiana Controlled Dangerous Substances (CDS) registration and a DEA registration. Federal law (the Ryan Haight Act framework administered by the DEA) requires a real-time, two-way audio-video evaluation before a first Schedule II prescription can be issued through telehealth. A phone-only consultation does not satisfy this requirement. General information on DEA telemedicine rules for controlled substances is available from the FDA, which coordinates with DEA on prescribing regulation, though the DEA's own site is the authoritative source and should be checked directly for the current rule text.

Before booking a telehealth visit in Louisiana, it is worth confirming three things directly with the practice: that the prescriber holds a Louisiana medical or advanced-practice license (not only a license from another compact state), that the visit itself will be conducted by live video rather than phone or asynchronous questionnaire, and that the practice can send an electronic prescription to a Louisiana pharmacy. Electronic prescribing of controlled substances (EPCS) has become the norm in most states, but confirming this with the specific pharmacy avoids a same-day delay.

Vyvanse (lisdexamfetamine dimesylate) is FDA-approved for ADHD in patients 6 and older and for moderate-to-severe binge eating disorder in adults; in Louisiana it can be prescribed by an MD, DO, NP, or PA either in person or via a live-video telehealth visit that meets the federal Schedule II evaluation standard, but Schedule II prescriptions cannot be refilled or transferred between pharmacies under federal law. This is the load-bearing fact set for anyone trying to start, continue, or move a Vyvanse prescription in the state, and it holds regardless of which specific clinic or platform a patient uses.

Who can prescribe Vyvanse in Louisiana

Any Louisiana-licensed MD, DO, nurse practitioner, or physician assistant with DEA Schedule II authority can write a Vyvanse prescription. Louisiana's advanced-practice framework allows nurse practitioners who have met the state's collaboration and practice-hour requirements to prescribe controlled substances; the exact current requirements should be confirmed with the Louisiana State Board of Nursing rather than assumed from general APRN scope-of-practice summaries, since state rules are updated periodically.

PAs prescribe under a collaborative practice agreement with a supervising physician. The supervising physician does not need to be physically present at the visit, but the agreement must specifically authorize Schedule II prescribing, a detail patients should ask the office to confirm before scheduling, since not every collaborative agreement includes it.

Psychiatrists and psychiatric nurse practitioners commonly manage ADHD stimulant treatment, but primary care physicians and pediatricians prescribe Vyvanse as well. Pediatricians can prescribe it for children age 6 and older under the FDA label. In parishes with limited psychiatric access, primary care and telehealth visits are often the practical route to an evaluation. A precise national estimate of what share of stimulant prescriptions originate in primary care versus specialty psychiatry is sometimes cited, but the figure inherited in earlier drafts of this page could not be verified against a real source and has been removed rather than repeated.

What an evaluation involves before starting Vyvanse

No blood test is required before starting Vyvanse. The core pre-prescribing workup is clinical:

• A structured ADHD or binge eating disorder diagnostic assessment, typically using validated tools such as the Vanderbilt Assessment Scale (children) or the Adult ADHD Self-Report Scale, with documentation of functional impairment across at least two settings and exclusion of mimicking conditions (anxiety, sleep disorders, thyroid dysfunction).
• A focused cardiovascular history and blood pressure and heart rate measurement, consistent with general guidance from the American Heart Association on cardiovascular screening before stimulant therapy. A resting EKG is not required for every patient; it is reasonable when there is a personal or family history suggestive of structural heart disease, arrhythmia, or sudden cardiac death.
• Baseline weight and, for children, height plotted on a growth chart, since stimulants can suppress appetite and slow growth in some pediatric patients.
• For binge eating disorder specifically, documentation of DSM-5 criteria including binge frequency, since this supports both clinical decision-making and insurer review.

Stimulant therapy is associated with modest average increases in blood pressure and heart rate in clinical trials, but the specific magnitude reported in an earlier version of this article was tied to an unverified citation and has been removed. A prescriber monitoring vital signs at follow-up visits, rather than a single baseline number, is the more clinically relevant point.

Does Louisiana Medicaid cover Vyvanse

As of this writing, Vyvanse is not on Louisiana Medicaid's preferred drug list for ADHD or binge eating disorder, and patients covered by Medicaid are generally directed toward covered generic alternatives such as mixed amphetamine salts or methylphenidate. This status can change, and it should be confirmed directly with Louisiana Medicaid or the patient's managed care organization before assuming coverage either way, since preferred drug lists are revised on a recurring schedule that is not reflected in this article.

A prescriber can submit a prior authorization request arguing medical necessity for brand or generic lisdexamfetamine specifically. The most commonly cited justification across state Medicaid programs generally is documented therapeutic failure of, or intolerance to, preferred formulary stimulants, meaning the patient tried an adequate dose for an adequate duration without acceptable symptom control, or had unacceptable side effects. Louisiana-specific approval rates, turnaround times, and peer-to-peer overturn rates were present in an earlier version of this page but could not be traced to a verifiable source; a reader who needs those numbers for a real decision should ask the prescribing office or the payer directly rather than rely on a percentage here.

Commercial insurance plans more often cover Vyvanse, but nearly always require prior authorization documenting the ADHD or BED diagnosis, prior medication trials, and the clinical rationale for choosing lisdexamfetamine over a covered alternative.

Cash price and generic availability

A generic lisdexamfetamine became available in the United States following Takeda's patent settlement with generic manufacturers; the FDA's own site (https://www.fda.gov/) is the authoritative place to confirm current approval and manufacturer status, since generic entry and supply can shift. Brand and generic cash prices vary by pharmacy, dose, and quantity, and change over time; specific dollar figures are not verified as current in this article and should be confirmed at the pharmacy counter or through a manufacturer savings program's own terms. Manufacturer coupon programs, where they exist, typically exclude government insurance (Medicaid, Medicare, Tricare), that exclusion is a stable feature of how these programs are structured, even though the specific discounted price is not.

503A compounding pharmacies in Louisiana

Louisiana licenses 503A compounding pharmacies through the Louisiana Board of Pharmacy. These pharmacies can prepare a patient-specific lisdexamfetamine order, for example, a dose strength between the manufacturer's fixed increments (10, 20, 30, 40, 50, 60, 70 mg), or a liquid suspension for a patient who cannot swallow capsules. A 503A pharmacy cannot produce batches for general distribution without an individual prescription for each patient.

Interstate shipment of a compounded Schedule II substance is subject to both DEA rules and the receiving state's pharmacy law. A patient relocating to Louisiana should confirm directly with the new pharmacy that it can receive an electronic Schedule II prescription rather than assuming a compounded prescription can simply transfer.

Moving to Louisiana: why an old Vyvanse prescription cannot just transfer

Federal law prohibits transferring a Schedule II prescription between pharmacies, including across state lines. A Vyvanse prescription filled at a pharmacy in another state cannot be called in, faxed, or electronically transferred to a Louisiana pharmacy. The patient needs a new prescription from a prescriber licensed to prescribe in Louisiana, whether that visit happens in person or by telehealth.

Requesting prior records, ADHD evaluations, rating scales, medication history, from the previous provider and bringing them to the new Louisiana prescriber can shorten the evaluation, since many prescribers will not require a full re-evaluation if recent documentation is thorough. Because Schedule II prescriptions cannot be refilled, patients should begin this process at least two to three weeks before their current supply runs out to avoid a treatment gap.

Monitoring after starting Vyvanse

A new prescription is required every month for a Schedule II medication; no refills are permitted under federal law. Louisiana allows a prescriber to issue up to three sequential 30-day prescriptions at one visit (for a 90-day total), which reduces the number of required office visits without violating the no-refill rule, provided each prescription specifies the earliest fill date.

Follow-up typically continues on a monthly basis during dose titration, then may shift to every three to six months once a patient is stable on a dose, with the prescription itself still renewed monthly. Monitoring parameters generally include blood pressure, heart rate, weight (and height in children), appetite, sleep, and mood. The FDA label for lisdexamfetamine (see the FDA's drug label database) carries warnings for cardiovascular risk, psychiatric adverse effects including new or worsening psychosis or mania, and growth suppression in pediatric patients, these are labeled warnings, not projections about any individual patient's risk.

A statement attributed to a pediatric ADHD guideline about "periodic reassessment of the need for continued treatment" appeared in an earlier draft of this page as a direct quotation. It has been removed because the citation could not be verified against the stated source. The general clinical principle, that ongoing stimulant therapy warrants at least an annual reassessment of continued need, updated symptoms, and functional outcome, is a reasonable practice standard, but a reader who needs the exact guideline language should consult the current guideline directly rather than rely on a quoted line here.

Evidence boundary: what is established, what is not

Established: Vyvanse is FDA-approved for ADHD (age 6+) and moderate-to-severe binge eating disorder in adults; it is a Schedule II controlled substance; federal law bars refills and pharmacy-to-pharmacy transfer of Schedule II prescriptions; Louisiana permits live-video telehealth prescribing of Schedule II stimulants by appropriately licensed prescribers.

Plausible but not confirmed here: specific percentages for prior-authorization approval or peer-to-peer overturn rates in Louisiana; the exact share of prescriptions written by primary care versus psychiatry; precise average blood pressure or heart rate changes at therapeutic doses. These may exist in the primary literature or in payer data, but the sources needed to state them precisely were not verifiable for this draft.

Not established / requires direct verification because it changes over time: Louisiana Medicaid's current preferred drug list status for Vyvanse; specific cash prices at Louisiana pharmacies; current manufacturer coupon terms; specific prior-authorization turnaround windows for any given insurer.

Verification checklist: stable facts vs. facts you must confirm today

Use this to separate what will still be true regardless of when you read this from what needs a same-day check with a prescriber, pharmacy, or payer.

Stable, unlikely to change without a formal rule change:

• Vyvanse is a Schedule II controlled substance under federal law.
• Schedule II prescriptions cannot be refilled and cannot be transferred between pharmacies, including across state lines.
• A live, two-way video visit (not phone-only) is required for an initial Schedule II telehealth prescription.
• FDA-approved indications are ADHD (age 6+) and moderate-to-severe binge eating disorder in adults.
• 503A compounding pharmacies may fill patient-specific, but not batch, orders.

Date-sensitive, confirm directly before you rely on it:

• Whether Louisiana Medicaid currently places Vyvanse on its preferred drug list.
• Your specific commercial plan's prior-authorization criteria and required documentation.
• Current cash price at your specific pharmacy, and whether a manufacturer coupon applies to your insurance type.
• Whether generic lisdexamfetamine is currently in stock at your pharmacy.
• The current supervising-physician and collaborative-agreement requirements for PAs and NPs prescribing Schedule II drugs in Louisiana.

Who to ask for each: Medicaid preferred drug list, Louisiana Medicaid or your managed care plan directly. Commercial prior authorization, your insurer's pharmacy benefits department. Price and stock, the specific pharmacy. Prescriber scope of practice, the Louisiana State Board of Medical Examiners, Board of Nursing, or the practice itself.

When to seek urgent care instead of waiting on a prescription

Chest pain, fainting, a racing or irregular heartbeat, signs of psychosis (hallucinations, severe paranoia), or suicidal thoughts after starting or adjusting a stimulant are reasons to seek urgent or emergency evaluation rather than waiting for a routine follow-up. These are labeled risks of stimulant medications generally, not specific to any one prescriber or pharmacy pathway described above.